Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

iver. Worldwide, primary liver cancer is the most common solid organ tumor, with more than 600,000 people diagnosed each year. The incidence of primary liver cancer is increasing due to underlying liver disease such as hepatitis infection and alcoholism. The overall five-year relative survival rate from primary liver cancer is about 10 percent, making it the cancer with the second poorest five-year survival rate. Liver cancer may be treated with surgery, radiation therapy or chemotherapy. The liver is also a common site for metastasis in other types of cancer, also known as secondary liver cancer. More than 500,000 people worldwide are diagnosed with secondary liver cancer each year; up to 50 percent of liver metastases are of colorectal cancer origin, while the remainder metastasize from a wide variety of primary cancer sites including breast and kidney.

About RNA Interference (RNAi)

RNA interference (or RNAi) is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the technology was recognized for its potential broad impact in medicine with the award of the 2006 Nobel Prize for Physiology or Medicine. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi has accelerated the understanding of these genes and their related pathways. Additionally, RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause targeted gene silencing.

About Alnylam

Alnylam is a biopharmaceutical company developing novel thera
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/21/2014)... Aug. 21, 2014 Asterias Biotherapeutics, Inc. (OTCBB: ... of regenerative medicine, announced today the appointments of Andrew ... newly expanded Board of Directors. With these additions, the ... of whom are independent. Andy Arno ... emerging growth companies. He is currently Managing Director of ...
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... LUTHERVILLE, Md. , Aug. 20, 2014 /PRNewswire/ ... today lauded the latest results achieved by the ... known as the National Precursor Log Exchange (NPLEx), ... enforcement officials track down methamphetamine offenders and make ... in Missouri blocked the ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... HILL, N.C., April 4, 2011 Cardioxyl Pharmaceuticals, ... abstracts from studies of its lead clinical candidate, ... 60th Annual Scientific Session & Expo in New ... abstract demonstrate CXL-1020,s ability to work independently from ...
... ICU Medical, Inc. (NASDAQ: ICUI ... at the Annual Scientific Meeting of the Society for ... showed that the MicroCLAVE neutral displacement needleless connector helps ... the incidence of hospital-acquired bloodstream infection when used in ...
Cached Medicine Technology:Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 2Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 3Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 4Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 5Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 2Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 3Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 4
(Date:8/21/2014)... effective vaccination, polio is considered nearly eradicated. Each year ... scientists of the University of Bonn, together with colleagues ... that was able to resist the vaccine protection to ... outbreak in the Congo in 2010. The pathogen could ... results appear now in the magazine PNAS . ...
(Date:8/21/2014)... August 21, 2014 Glioblastoma Multiforme ... Therapeutic Approaches Target High Unmet Need in Newly ... of the Glioblastoma Multiforme (GBM) therapeutics market within ... and Japan. The report provides estimates of market ... 2020. It also covers disease epidemiology, treatment algorithms, ...
(Date:8/21/2014)... 2014 One of the emerging trends ... experience is an increasing adoption of non-invasive administration products. ... the patient through their convenient application, they find more ... a medical device used for the administration of drugs ... and paranasal sinus such as allergic and non-allergic rhinitis ...
(Date:8/21/2014)... Hospital officials, community leaders and elected officials ... new building at Mount Sinai Queens, marking the completion ... expansion and modernization project. During the event, hospital ... Kaufman, Chairman of the nearby Kaufman Astoria Studios, for ... will be named. The project, which began late ...
(Date:8/21/2014)... According to a new market research report "Near Field ... Auxiliary), Application (Payment, Transportation, Booking, Data Sharing, Service, Access ... - Global Forecasts to 2022", published by MarketsandMarkets, the ... by 2022 at an estimated CAGR of 8.83% from ... and 105 Figures spread through 298 Pages and in-depth ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 3Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 4Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 5Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 6Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 7Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 2Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 3Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 4Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 2Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 3Health News:Near Field Communication Market by Product (IC/Chips, Tags, Readers, and Auxiliary) Worth $16.25 Billion by 2022 – New Report by MarketsandMarkets 4
... , MONDAY, April 9 (HealthDay News) -- People ... problems, such as ulcers and bleeding, and also for ... The findings highlight the need to develop new ... arthritis patients, according to the Mayo Clinic researchers. ...
... than 60 percent of breast cancer survivors report at ... diagnosis, according to a new study led by a ... University of Pennsylvania. The findings are part of a ... late effects of breast cancer treatment and creating strategies ...
... , MONDAY, April 9 (HealthDay News) -- Hispanics and ... and Medicare and Medicaid patients are less likely to receive ... says. University of Michigan School of Public Health researchers ... were 1.5 times more likely to receive antidepressants than blacks ...
... , (WASHINGTON, April 9, 2012) A novel anti-leukemia compound with ... (T-ALL), suggesting its potential to become a new highly targeted ... according to results from a study published ... of the American Society of Hematology (ASH). ...
... 262 Pages | $29.95 | ISBN13: 9780199892594) "Roberta Ness teaches how ... as its subject, Dr. Ness shows how, with a little know-how and ... selves.", ... Medicine, National Academies of Science "Great science depends on innovative ...
... in-patient rehabilitation are more likely to land back in ... poorly, show signs of depression and lack social support ... Branch (UTMB) at Galveston. Hospital readmission for older adults ... billion annually. , Among the first of such ...
Cached Medicine News:Health News:Gastro Woes Often Strike Rheumatoid Arthritis Patients 2Health News:Breast cancer patients suffer treatment-related side effects long after completing care 2Health News:Breast cancer patients suffer treatment-related side effects long after completing care 3Health News:Minorities, Medicare Recipients Less Likely to Get Antidepressants 2Health News:Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment 2Health News:Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment 3Health News:Innovation Generation 2Health News:Innovation Generation 3Health News:Predictors identified for rehospitalization among post-acute stroke patients 2Health News:Predictors identified for rehospitalization among post-acute stroke patients 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: